Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease
A feasibility study
Shmuel Fuchs, MD*,*,
Lowell F. Satler, MD*,
Ran Kornowski, MD
,
Petros Okubagzi, MD*,
Giora Weisz, MD
,
Richard Baffour, MD*,
Ron Waksman, MD*,
Neil J. Weissman, MD*,
Manuel Cerqueira, MD*,
Martin B. Leon, MD
and
Stephen E. Epstein, MD*
* Cardiovascular Research Institute, MedStar Research Institute, Washington Hospital Center, Washington, DC, USA
Rabin Medical Center, Petach-Tikva, Israel
Cardiovascular Research Foundation, Lenox Hill Hospital, New York, New York, USA

View larger version (55K):
[in a new window]
|
Figure 1 Left ventricular electromechanical maps (left oblique, bottom view projection) after 12 intramyocardial injections of autologous bone marrow. Injections were delivered into an ischemic right coronary artery territory. Local shortening (A) and unipolar voltage (B) amplitudes are color-coded and the exact location of each of the injection sites is tagged on the maps in real-time (black tags).
|
|

View larger version (25K):
[in a new window]
|
Figure 2 Semiquantitative stress scores of segments with baseline reversible ischemia within injected and remote coronary artery territories. SPECT = single-photon emission computed tomography.
|
|
Copyright © 2003 by the American College of Cardiology Foundation.